PubRank

John Morser

Author PubWeight™ 56.10‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010 3.57
2 The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003 2.94
3 Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009 1.96
4 Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A 2005 1.84
5 Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011 1.63
6 Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. Respir Med 2010 1.54
7 Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003 1.43
8 Genomic structures of the human and murine corin genes and functional GATA elements in their promoters. J Biol Chem 2002 1.37
9 Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin. J Biol Chem 2003 1.27
10 Furin-mediated processing of Pro-C-type natriuretic peptide. J Biol Chem 2003 1.22
11 Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem 2002 1.21
12 Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002 1.13
13 Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum 2009 1.07
14 Rev-erbalpha upregulates NF-kappaB-responsive genes in vascular smooth muscle cells. FEBS Lett 2004 1.03
15 Efficacy of a novel class of RNA interference therapeutic agents. PLoS One 2012 0.99
16 Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease. Surgery 2010 0.97
17 A case of fulminant type 1 diabetes with coxsackie B4 virus infection diagnosed by elevated serum levels of neutralizing antibody. Diabetes Res Clin Pract 2009 0.97
18 Proteolytic cleavage of chemerin protein is necessary for activation to the active form, Chem157S, which functions as a signaling molecule in glioblastoma. J Biol Chem 2011 0.91
19 Characterization of a small molecule PAI-1 inhibitor, ZK4044. Thromb Res 2004 0.90
20 Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A 2013 0.90
21 RORalpha1 and RORalpha4 suppress TNF-alpha-induced VCAM-1 and ICAM-1 expression in human endothelial cells. FEBS Lett 2004 0.88
22 Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. J Biol Chem 2012 0.88
23 Differential role of regulatory T cells in early and late stages of pulmonary fibrosis. Immunobiology 2012 0.88
24 Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis. Am J Respir Cell Mol Biol 2011 0.87
25 Microfluidic impedance cytometer for platelet analysis. Lab Chip 2013 0.87
26 Chemerin158K protein is the dominant chemerin isoform in synovial and cerebrospinal fluids but not in plasma. J Biol Chem 2011 0.86
27 A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thromb Haemost 2007 0.85
28 Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice. Arterioscler Thromb Vasc Biol 2010 0.85
29 Neuroprotective effects of recombinant thrombomodulin in controlled contusion spinal cord injury implicates thrombin signaling. J Neurotrauma 2004 0.84
30 Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice. J Cell Physiol 2005 0.84
31 Atherosclerosis amelioration by moderate alcohol consumption is associated with increased circulating levels of stromal cell-derived factor-1. Circ J 2011 0.83
32 Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system. Am J Respir Cell Mol Biol 2013 0.83
33 Inhibition of allergic bronchial asthma by thrombomodulin is mediated by dendritic cells. Am J Respir Crit Care Med 2010 0.83
34 Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis. Am J Pathol 2006 0.81
35 A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007 0.81
36 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) signals through retinoic acid receptor-related orphan receptor-alpha but not peroxisome proliferator-activated receptor-gamma in human vascular endothelial cells: the effect of 15d-PGJ2 on tumor necrosis factor-alpha-induced gene expression. Arterioscler Thromb Vasc Biol 2005 0.80
37 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett 2006 0.80
38 Role of the coagulation system in allergic inflammation in the upper airways. Clin Immunol 2008 0.80
39 Lipopolysaccharide attenuates thrombolysis in batroxobin-induced lung vasculature fibrin deposition but not in ferrous chloride-induced carotid artery thrombus in rats: role of endogenous PAI-1. Thromb Res 2003 0.80
40 Differential gene expression in thrombomodulin (TM; CD141)(+) and TM(-) dendritic cell subsets. PLoS One 2013 0.80
41 Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem 2007 0.79
42 The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. J Biol Chem 2008 0.79
43 Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation. J Biol Chem 2002 0.79
44 Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res 2008 0.79
45 Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs. Thromb Haemost 2003 0.78
46 Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma. Lung 2011 0.78
47 Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency. Thromb Haemost 2008 0.78
48 Structures of potent selective peptide mimetics bound to carboxypeptidase B. Acta Crystallogr D Biol Crystallogr 2008 0.78
49 Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets. Thromb Res 2008 0.78
50 The coagulation and protein C pathways in patients with sleep apnea. Lung 2009 0.77
51 Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice. Front Biosci 2002 0.77
52 P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1. Thromb Haemost 2004 0.77
53 Different bile concentration of micafungin and itraconazole in a patient with candidal cholecystitis. J Infect 2009 0.77
54 Presence of thrombin-activatable fibrinolysis inhibitor in Helicobacter pylori-associated gastroduodenal disease. Helicobacter 2009 0.76
55 A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization. Thromb Haemost 2007 0.76
56 Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity. J Biol Chem 2003 0.75
57 Erratum. Amelioration of Diabetes by Protein S. Diabetes 2016;65:1940-1951. Diabetes 2016 0.75
58 Inhibition of rho-kinase by hydroxyfasudil prevents vasopressin-induced myocardial ischemia in Donryu rats by attenuating coronary vasoconstriction. Pharmacology 2005 0.75
59 Discovery and characterization of a potent and selective non-amidine inhibitor of human factor Xa. Biochem Pharmacol 2003 0.75